Predictors of Heart Failure After ST-segment Elevation Myocardial Infarction (HF-EXPRESS)

Heart Failure and ST Elevation Myocardial Infarction Clinical Trial

— HF-EXPRESS  

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02650934
• Other study ID #: 114S309
• Status: Recruiting
• Phase: N/A
• First received: January 7, 2016
• Last updated: January 7, 2016
• Start date: June 2015
• Est. completion date: June 2019

Study information

• Verified date: June 2015
• Source: Dr. Nafiz Korez Sincan State Hospital
• Contact: Ferhat Eyyupkoca, MD
• Phone: +905056864352
• Email: ferhateyupkoca[@]hotmail.com
• Is FDA regulated: No
• Health authority: Turkey: Ministry of public health
• Study type: Observational

Clinical Trial Summary

Objective: The purpose of this project is to study the post miyocardial infaction (MI) damage and subsequently developed post-infarct cardiac repair process on the basis of cellular, molecular and imaging techniques. Besides this, whole genomesequencing and analysis (GWAS) will be performed to determine common varying genetic loci in order to anticipate whetherthese findings and its related pathways would be the predictors of adverse remodeling after MI or not.

Description:

A brief description of the issue and the original value of the subject: Epidemiological studies show a clear increase ininfarct-related complications due to increased survival after MI and aging population. Heart failure is the most prevalent complication after MI, which has reached epidemic proportions in western societies. For the period between 2010 and 2030,according to projections made in developed countries, about 10% increment in all cardiovascular disease is being predictedhowever increment in heart failure (HF) would be such a dramatic figure which is about 25%. HF is an increasing burden tosociety and healthcare systems, since its prevalence and incidence is dramatically increasing. There has not been aprospective study that assesses the exact cellular and geometric course after MI in human. This study will allow us tounderstand the behavior of cells involved in cardiac repair after MI. In addition, it will show us the exact functional andgeometric course after MI. Finally, the current study will also provide novel diagnostic and therapeutic targets via genomic andproteomic studies. All together, we envision to find new efficient ways to identify/treat patients at risk to develop HF after MI.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 312
• Est. completion date: June 2019
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

18-80 years old patients with myocardial infarction in the first 12 hours TIMI 3 flow following PCI

Exclusion Criteria:

Right ventiricular myocardial infarction Cardiogenic shock History of CABG, PCI or valvular disease History of Cardiomyopathy severe LV hypertrophy No reflow after PCI Chronic kidney disease (GFR<60) Systemic inflammatory disease

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure and ST Elevation Myocardial Infarction
• Infarction
• Myocardial Infarction

Intervention

Procedure:
• Percutanous coronary intervention

Locations

Country	Name	City	State
Turkey	Dr.Nafiz Korez state hospital	Ankara

Sponsors (4)

Lead Sponsor	Collaborator
Dr. Nafiz Korez Sincan State Hospital	Ankara Ataturk Training and Research Hospital, Ankara, Turkey, Ankara Diskapi Training and Research Hospital, Ankara, Turkey, Ankara Numune Training and Research Hospital, Ankara, Turkey

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Ørn S, Ueland T, Manhenke C, Sandanger Ø, Godang K, Yndestad A, Mollnes TE, Dickstein K, Aukrust P. Increased interleukin-1ß levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction — View Citation

Palazzuoli A, Beltrami M, Gennari L, Dastidar AG, Nuti R, McAlindon E, Angelini GD, Bucciarelli-Ducci C. The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. Int J Cardiovasc Ima — View Citation

Scott AE, Semple SI, Redpath TW, Hillis GS. Low-dose dobutamine adds incremental value to late gadolinium enhancement cardiac magnetic resonance in the prediction of adverse remodelling following acute myocardial infarction. Eur Heart J Cardiovasc Imaging — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiovascular death, nonfatal MI, stroke		2 years	Yes